Actor Colin McFarlane is calling on black men to participate in a prostate cancer screening trial, emphasizing the need for further evidence to support screening programs. The National Screening Committee’s recent decision to advise against widespread prostate cancer screening for most men in the UK has sparked concern. McFarlane, who was diagnosed with prostate cancer in 2022, expressed his disappointment, highlighting the stark disparity in prostate cancer risk between black men and the general population. According to Prostate Cancer UK, black men are twice as likely to be affected by prostate cancer, with a one in four chance of developing the disease. The committee’s recommendation limits screening to men with specific genetic mutations (BRCA variants) between the ages of 45 and 61, which McFarlane believes is insufficient. He argues that the current lack of clinical trials for black men introduces uncertainties about the impact of screening. McFarlane’s call to action includes urging black men to sign up for the Transform trial, which aims to find the safest, most accurate, and cost-effective screening methods. He also encourages GPs to provide PSA tests to men who request them, emphasizing the importance of early detection despite the absence of symptoms or pain. The actor’s advocacy underscores the critical need for diverse representation in prostate cancer research and the potential benefits of proactive screening for black men.